atp13a2-protein

atp13a2-protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ATP13A2 Protein (PARK9)</th>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9BYU8" target="_blank">Q9BYU8</a></td>
</tr>
<tr>
<td class="label">Gene</td>
<td><a href="/genes/atp13a2">ATP13A2</a></td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>3,978 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~446 kDa</td>
</tr>
<tr>
<td class="label">ATPase Type</td>
<td>P5B-type (P-type ATPase family)</td>
</tr>
<tr>
<td class="label">Subcellular Location</td>
<td>Lysosomal membrane, Late endosomes</td>
</tr>
<tr>
<td class="label">Transmembrane Domains</td>
<td>10</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Brain (substantia nigra, basal ganglia), Liver, Kidney</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/diseases/parkinsons-disease">Parkinson's Disease</a>, <a href="/diseases/kufor-rakeb-syndrome">Kufor-Rakeb Syndrome</a>, Neuronal Ceroid Lipofuscinosis</td>
</tr>
</table>

ATP13A2 Protein (PARK9)

Overview

atp13a2-protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ATP13A2 Protein (PARK9)</th>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9BYU8" target="_blank">Q9BYU8</a></td>
</tr>
<tr>
<td class="label">Gene</td>
<td><a href="/genes/atp13a2">ATP13A2</a></td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>3,978 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~446 kDa</td>
</tr>
<tr>
<td class="label">ATPase Type</td>
<td>P5B-type (P-type ATPase family)</td>
</tr>
<tr>
<td class="label">Subcellular Location</td>
<td>Lysosomal membrane, Late endosomes</td>
</tr>
<tr>
<td class="label">Transmembrane Domains</td>
<td>10</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Brain (substantia nigra, basal ganglia), Liver, Kidney</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/diseases/parkinsons-disease">Parkinson's Disease</a>, <a href="/diseases/kufor-rakeb-syndrome">Kufor-Rakeb Syndrome</a>, Neuronal Ceroid Lipofuscinosis</td>
</tr>
</table>

ATP13A2 Protein (PARK9)

Overview

ATP13A2 (also known as PARK9) is a member of the P-type ATPase family of cation transporters. As a P5B-type ATPase, this protein utilizes ATP hydrolysis to transport cationic substrates across biological membranes, primarily localizing to lysosomal and late endosomal membranes throughout the body.[@[i2022]] The protein plays a critical role in maintaining metal cation homeostasis within the lysosomal lumen, particularly for manganese (Mn²⁺), zinc (Zn²⁺), and potentially iron (Fe²⁺/Fe³⁺).

The ATP13A2 protein is encoded by the [ATP13A2 gene](/genes/atp13a2), located on chromosome 1p36.13. With a molecular weight of approximately 446 kDa and containing 3,978 amino acids, ATP13A2 is one of the largest known P-type ATPases. The protein is composed of 10 transmembrane domains that form a channel for cation passage, along with conserved cytoplasmic domains responsible for ATP binding and phosphorylation.

Mutations in ATP13A2 cause Kufor-Rakeb syndrome (KRS), a rare autosomal recessive form of parkinsonism characterized by early-onset Parkinsonism, supranuclear gaze palsy, and pyramidal signs. More recent research has implicated ATP13A2 dysfunction in the broader pathogenesis of sporadic Parkinson's disease, where the protein plays essential roles in lysosomal function, autophagy, and neuronal survival.

Protein Structure

Domain Architecture

ATP13A2 exhibits the canonical domain structure of P-type ATPases, adapted for its role as a lysosomal cation transporter:

Transmembrane Domain:

• 10 transmembrane helices (M1-M10) that span the lysosomal membrane
• Form a channel allowing passage of cationic substrates
• The cation-binding site is located within the transmembrane region
• Conserved residues in the channel determine ion specificity

• Actuator domain (A-domain): Contains the conserved DKTGTLT motif with an essential aspartate residue that undergoes phosphorylation during the catalytic cycle
• Phosphorylation domain (P-domain): Binds ATP and contains the phosphorylation site
• Nucleotide-binding domain (N-domain): Catalyzes ATP hydrolysis and couples energy to conformational changes

Structural Features

Cryo-electron microscopy studies have revealed several key structural features:

Molecular Function

Lysosomal Cation Transport

The primary physiological function of ATP13A2 is the ATP-dependent transport of cationic substrates across the lysosomal membrane:

Manganese Transport:

• Highest affinity substrate with Km values in the 10-20 μM range
• Essential for lysosomal manganese sequestration, preventing cytoplasmic accumulation
• Critical for neuronal health given manganese's neurotoxicity at elevated concentrations

• Lower affinity (Km ~ 50-100 μM) but physiologically significant
• Modulates synaptic zinc signaling
• Important for lysosomal zinc homeostasis

• Variable affinity depending on oxidation state
• May contribute to preventing iron-mediated oxidative damage
• The exact substrate profile remains under investigation

Catalytic Cycle

The P-type ATPase catalytic cycle involves several key steps:

This vectorial transport mechanism allows cells to concentrate cations within lysosomes against their electrochemical gradient.

Role in Lysosomal Function

Beyond cation transport, ATP13A2 supports overall lysosomal function:

• pH maintenance: Cation transport contributes to lysosomal electrochemical balance
• Enzyme activation: Proper lysosomal pH (~4.5-5.0) is required for cathepsin activity
• Membrane potential: ATP13A2 activity influences the lysosomal membrane potential

Expression and Localization

Tissue Distribution

ATP13A2 protein shows highest expression in:

Central Nervous System:

• Substantia nigra pars compacta (dopaminergic neurons)
• Basal ganglia (caudate nucleus, putamen, globus pallidus)
• Cerebral cortex (particularly layer 5 pyramidal neurons)
• Hippocampus (CA1 and CA3 regions)
• Cerebellum (Purkinje cells)

• Liver (hepatocytes)
• Kidney (renal tubules)
• Pancreas (islet cells)

Subcellular Localization

ATP13A2 localizes primarily to:

• Lysosomal membranes (the predominant location)
• Late endosomal membranes
• Some reports suggest minor ER localization during biosynthesis

Role in Neurodegeneration

Lysosomal Dysfunction

Loss of ATP13A2 function leads to progressive lysosomal dysfunction:

Autophagy Impairment

ATP13A2 deficiency significantly impairs the autophagy-lysosomal pathway:

• Reduced autophagosome formation
• Impaired fusion of autophagosomes with lysosomes
• Decreased clearance of autophagy substrates
• Accumulation of damaged organelles and protein aggregates

Alpha-Synuclein Interaction

The relationship between ATP13A2 and alpha-synuclein is bidirectional and significant:

• ATP13A2 deficiency promotes alpha-synuclein aggregation
• Alpha-synuclein accumulation further impairs lysosomal function
• This creates a vicious cycle promoting neurodegeneration
• Restoring ATP13A2 function may break this cycle

Mitochondrial Dysfunction

ATP13A2 loss leads to mitochondrial abnormalities:

• Reduced mitochondrial membrane potential
• Increased reactive oxygen species (ROS) production
• Impaired mitophagy
• Enhanced susceptibility to apoptotic stimuli
• Complex I deficiency

Metal Homeostasis Disruption

ATP13A2 deficiency causes widespread metal dysregulation:

• Manganese: Cytosolic and mitochondrial accumulation
• Zinc: Altered synaptic zinc handling
• Iron: Increased free iron, promoting Fenton chemistry
• Copper: Potential dysregulation

Disease Mechanisms

Kufor-Rakeb Syndrome

Biallelic loss-of-function mutations in ATP13A2 cause Kufor-Rakeb syndrome through complete loss of protein function:

• No functional cation transport
• Severe lysosomal dysfunction
• Progressive neuronal loss
• Characteristic parkinsonian phenotype

Sporadic Parkinson's Disease

Common genetic variants in ATP13A2 may contribute to sporadic PD risk through:

• Partial loss of function
• Subtle impairment of lysosomal function
• Reduced capacity to handle cellular stress
• Gene-environment interactions

Neuronal Ceroid Lipofuscinosis (NCL)

ATP13A2 mutations can cause a form of NCL characterized by:

• Lysosomal storage of lipofuscin-like material
• Progressive visual loss
• Seizures
• Childhood onset

Therapeutic Implications

Gene Therapy

AAV-mediated delivery of ATP13A2 represents a promising therapeutic approach:

• Restoration of functional protein in affected neurons
• Potential for disease modification
• Preclinical studies demonstrating feasibility
• Challenges: targeting, dosing, immune response

Small Molecule Activators

Pharmacological approaches to enhance ATP13A2 function:

• Transport activity enhancers: Increase ATP13A2 catalytic activity
• Pharmacological chaperones: Stabilize mutant protein, improve trafficking
• Autophagy modulators: Compensate for ATP13A2 deficiency

Autophagy Enhancement

Drugs that boost autophagy may compensate for ATP13A2 deficiency:

• Rapamycin and analogs (mTOR inhibitors)
• Natural compounds (resveratrol, curcumin)
• Small molecule activators of TFEB

Metal Chelation

For patients with manganese dyshomeostasis:

• EDTA and CaNa₂EDTA for manganese removal
• Potential for combination therapy
• Requires careful monitoring

Interaction Network

ATP13A2 interacts with several proteins relevant to neurodegeneration:

• [PINK1](/genes/pink1): Both involved in mitochondrial quality control
• [Parkin](/genes/parkin): Cooperates in mitophagy pathway
• [Alpha-synuclein](/proteins/alpha-synuclein): ATP13A2 deficiency promotes aggregation
• LAMP2A: Component of chaperone-mediated autophagy
• Cathepsins: Lysosomal proteases dependent on proper lysosomal pH
• GBA: Lysosomal enzyme whose mutations increase PD risk

Animal Models

Mouse Models

• Global knockout: Motor deficits, alpha-synuclein pathology
• Conditional knockout: Region-specific phenotypes
• Transgenic: Human ATP13A2 expression studies

Non-Mammalian Models

• C. elegans: Knockout shows manganese sensitivity
• Drosophila: Loss leads to neurodegeneration
• Zebrafish: Developmental studies

Biomarkers

Potential biomarkers for ATP13A2-related disease:

• Blood manganese: Often elevated
• Lysosomal pH: Elevated in patient cells
• Autophagic markers: LC3, p62 accumulation
• Neurofilament light chain: Elevated in CSF

Research Directions

Key areas for future research:

Summary

ATP13A2 is a lysosomal P5B-type ATPase critical for metal cation transport and neuronal survival. The protein maintains lysosomal function through ATP-dependent transport of manganese, zinc, and other cations. Loss of ATP13A2 function causes Kufor-Rakeb syndrome and contributes to sporadic Parkinson's disease pathogenesis through lysosomal dysfunction, impaired autophagy, and metal homeostasis disruption. Understanding ATP13A2 function provides insights into neurodegenerative disease mechanisms and identifies potential therapeutic targets.

See Also

• [ATP13A2 Gene](/genes/atp13a2)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Kufor-Rakeb Syndrome](/diseases/kufor-rakeb-syndrome)
• [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)
• [Autophagy in Neurodegeneration](/mechanisms/autophagy-neurodegeneration)
• [Mitochondrial Dysfunction in PD](/mechanisms/mitochondrial-dysfunction-pd)
• [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)

References